ALUR vs. SKIN, TCMD, SGHT, INO, OBIO, ANGO, UTMD, RCEL, TLSI, and NPCE
Should you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include Beauty Health (SKIN), Tactile Systems Technology (TCMD), Sight Sciences (SGHT), Inovio Pharmaceuticals (INO), Orchestra BioMed (OBIO), AngioDynamics (ANGO), Utah Medical Products (UTMD), AVITA Medical (RCEL), TriSalus Life Sciences (TLSI), and NeuroPace (NPCE). These companies are all part of the "surgical & medical instruments" industry.
Beauty Health (NASDAQ:SKIN) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.
Allurion Technologies has lower revenue, but higher earnings than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
Beauty Health received 37 more outperform votes than Allurion Technologies when rated by MarketBeat users. However, 100.00% of users gave Allurion Technologies an outperform vote while only 48.78% of users gave Beauty Health an outperform vote.
In the previous week, Beauty Health had 18 more articles in the media than Allurion Technologies. MarketBeat recorded 21 mentions for Beauty Health and 3 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 0.92 beat Beauty Health's score of 0.33 indicating that Beauty Health is being referred to more favorably in the media.
Beauty Health has a net margin of -20.48% compared to Beauty Health's net margin of -117.30%. Beauty Health's return on equity of 0.00% beat Allurion Technologies' return on equity.
Beauty Health currently has a consensus target price of $6.29, indicating a potential upside of 184.42%. Allurion Technologies has a consensus target price of $5.00, indicating a potential upside of 231.13%. Given Beauty Health's stronger consensus rating and higher probable upside, analysts clearly believe Allurion Technologies is more favorable than Beauty Health.
93.3% of Beauty Health shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 41.0% of Beauty Health shares are held by company insiders. Comparatively, 20.0% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Beauty Health has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.13, meaning that its stock price is 113% less volatile than the S&P 500.
Summary
Beauty Health beats Allurion Technologies on 10 of the 17 factors compared between the two stocks.
Get Allurion Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allurion Technologies Competitors List
Related Companies and Tools
